Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formulation Selection and Optimization of BI 894416 in Healthy Men
NCT04232839Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 894416 in asthma (10 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity. Started Feb 2020; status: terminated.
02
Drugs
BI 894416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04232839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232839.